Roche is a Swiss pharmaceutical group, founded in 1896 by Fritz Hoffmann-La Roche, among the world leaders in the sector. As NovartisRoche, one of its main competitors, is headquartered in Basel, Switzerland. The company is the world leader in cancer medications and virology. It markets some famous products such as Valium, Xenical, and the famous Tamiflu. Roche operates in 150 countries and now owns Genentech, an American laboratory specializing in biotechnology.
The title offers an interesting long-term yield, at 3.24%, which it owes in particular to a very sustained growth rate of its distributions (20.88% in the medium term). Roche has been able to increase its dividend for 16 consecutive years, which is not bad, but not comparable to some of our giants. portfolioThe impressive dividend growth of recent years has had an impact on the distribution ratio which currently stands at 59.35%. This nevertheless remains within reasonable proportions and allows the company to ensure the payment of its dividend in the future, even in the event of a difficult transition. volatility of the title is quite high (compared to our standards), since it amounts to 17,57%, significantly more than its competitor Novartis (11,69%).
Roche has been added to our portfolio, as part of our currency diversification strategy. It still falls short of certain criteria, which means that it is currently in observation phase (or in "hold" for those who already have it), but it is a value which has a certain number of qualities and which we wish to follow in the future.
Discover more from dividendes
Subscribe to get the latest posts sent to your email.